NSC 23766

Catalog No.S8031

For research use only.

NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA.

NSC 23766 Chemical Structure

CAS No. 1177865-17-6

Selleck's NSC 23766 has been cited by 78 publications

Purity & Quality Control

Choose Selective Rho Inhibitors

Biological Activity

Description NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA.
Targets
Rac GTPase [1]
(Cell-free assay)
50 μM
In vitro

NSC23766 is identified to fit into a surface groove of Rac1 known to be critical for GEF specification. NSC23766 effectively inhibits Rac1 binding and activation by the Rac-specific GEF Trio or Tiam1 in a dose-dependent manner without interfering with the closely related Cdc42 or RhoA binding or activation by their respective GEFs or with Rac1 interaction with BcrGAP or effector PAK1. [1] NSC 23766 is active in regulating Rac GTPase functions on cytoskeleton and many cell functions including cell cycle, cell growth, adhesion, migration and gene transcription. NSC 23766 (50 μM) potently blocks serum or platelet-derived growth factor-induced Rac1 activation and lamellipodia formation without affecting the activity of endogenous Cdc42 or RhoA in NIH 3T3 cells. NSC 23766 reduces Trio or Tiam1 but not Vav, Lbc, Intersectin, or a constitutively active Rac1 mutant-stimulated NIH 3T3 cells growth and suppresses Trio, Tiam1, or Ras-induced cell transformation. NSC23766 dose-dependently inhibits PC-3 cells proliferation and anchorage-independent growth. 25 μM NSC23766 inhibits the PC-3 cell invasion through Matrigel by 85%. [1] 50 μM NSC 23766 inhibits thrombin-induced activation of Rac1 an d Rac2 in human platelets, as well as platelet aggregation. [2] NSC23766 prevents Aβ40 and Aβ42 production in swAPP-HEK293cells without affecting Notch and sAPPα. NSC23766 prevents γ-secretase activity in cell, but not act as a direct γ-secretase inhibitor. NSC23766 dose-dependently reduces levels of secreted and intracellular Aβ40 with IC50 of 48.94 μM. 50 μM NSC 23766 inhibits release of Aβ42 by 57.97%. [3] NSC23766 regulates endothelial nitric oxide synthase expression and endothelial function. 100 μM NSC23766 represses the eNOS promoter activity by 60% in bovine aortic ECs and by 30% to 35% in bEND.3 cells. Inhibition of Rac1 with NSC23766 destabilizes eNOS mRNA and shortens its half-life to 17 hours. NSC23766 dose-dependently attenuates ACh-induced relaxation of wild-type mice aortic rings. [4] NSC23766 inhibits cell growth and induces apoptosis. NSC23766 decreases MDA-MB-468 and MDA-MB-231 cells viability in a dose-dependent manner with IC50 of ~10 μM, which is not correlated with the status of estrogen receptor (ER), progesterone receptor (PR), Her2, and p53 mutation. NSC23766 has little effect on the survival of the MCF12A normal mammary epithelial cells. After 24 hours expose to NSC 23766, MDA-MB-231 cells showes an increase from 41% to 65% in G1 phase and a concomitant decrease in S and G2-M phases. 100 μM NSC23766 induces a six-fold increase of apoptotic MDA-MB-468. The inhibition of NSC23766 on cell cycle arrest or apoptosis in breast cancer cells is mediated by downregulation of cyclin D1, survivin, and X-linked inhibitor of protein apoptosis. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RA4 MoXZSpVv[3Srb36gRZN{[Xl? NWTSfHFYPTBizszN MVWyOEBp MmO5bY5pcWKrdIOgUYF1emmpZXygbY53[XOrb36= M3\melxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkKyN|A5Lz5zN{[yNlMxQDxxYU6=
RA3 Mn7lSpVv[3Srb36gRZN{[Xl? M3jlbVUxKM7:TR?= NGDyZ5ozPCCq MWrpcohq[mm2czDNZZRzcWenbDDpcpZie2mxbh?= NHPY[I89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[yNlMxQCd-MUe2NlI{ODh:L3G+
RA2 MVLGeY5kfGmxbjDBd5NigQ>? M4f1OVUxKM7:TR?= NIjl[3YzPCCq MlHmbY5pcWKrdIOgUYF1emmpZXygbY53[XOrb36= NH34d|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[yNlMxQCd-MUe2NlI{ODh:L3G+
RA1 M2O5TmZ2dmO2aX;uJGF{e2G7 MVy1NEDPxE1? NFi0Z3ozPCCq NG\CdlhqdmirYnn0d{BO[XS{aXflcEBqdn[jc3nvci=> NGP5RmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[yNlMxQCd-MUe2NlI{ODh:L3G+
RA-FLS (RA2)  M3XVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnyNlUwPTBizszN NVHXSFNiOS17IHS= NELDXWZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NXrmN29ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NlI{ODhpPkG3OlIzOzB6PD;hQi=>
IEC-6  MYDGeY5kfGmxbjDBd5NigQ>? NV7Wd|c2OTJyINM1US=> NGn6eYs1NzZxODDo NXjpVXBReHKndnXueJMhfGinIHnuZ5Jm[XOnZDDhZ5RqfmG2aX;uJI9nKE[DSzDheEA3KGGwZDC4JIg> NXHJXWtCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OFg1PjFpPkKwOFQ5PDZzPD;hQi=>
MDA-MB-231  M1LXcWZ2dmO2aX;uJGF{e2G7 MVK1NE8yODBizszN M33VO|Q5KGh? MofsbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHTlZ5Jm[XOnIHnuJJBpd3OyaH;yfYxifGmxbjDv[kBxPjVic4XieY5qfA>? NX7IdWF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MDA-MB-468 M{T2fWZ2dmO2aX;uJGF{e2G7 NX72UJFbPTBxMUCwJO69VQ>? NUHwUVFCPDhiaB?= MVvpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1cW:wIH;mJJA3PSC|dXL1col1 MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MDA-MB-231  MXjGeY5kfGmxbjDBd5NigQ>? M33PUVUxNzFyMDFOwG0> NG[4c2ozPCCq NWnNOIxvcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCMTlugbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MDA-MB-468 MkL0SpVv[3Srb36gRZN{[Xl? NWXNSpVvPTBxMUCwJO69VQ>? Mn\iNlQhcA>? NEPlSZlqdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKEqQSzDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXz3ZlFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MDA-MB-468 MV\GeY5kfGmxbjDBd5NigQ>? MYCxNFAh|ryP NFLueogzPCCq MYXpcohq[mm2c9MgZ4F{eGG|ZT2zJIFkfGm4YYTpc47DqA>? NHj5OY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
MDA-MB-468 M1u0dGFxd3C2b4Ppd{BCe3OjeR?= MWW1NE8yODBizszN MmjUNlQhcA>? NH\acmtqdmS3Y3XzJIFxd3C2b4Ppdy=> NU\DbW15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
T47D NIK3cmNHfW6ldHnvckBCe3OjeR?= Mkm3NVAxKM7:TR?= MnfpOFghcA>? NEK1[4hqdmO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJIlvKEdzwrDwbIF{\SCjbnSg[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDpckBUKGGwZDDHNk1OKHCqYYPld:Kh M3TqcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
MCF7 NEPMV3pHfW6ldHnvckBCe3OjeR?= M{G5WlExOCEQvF2= MoLZOFghcA>? MnzzbY5kemWjc3XzJJRp\SClZXzsJI52dWKncjDpckBIOcLicHjhd4Uh[W6mIHTlZ5Jm[XOnczD0bIUh[2WubDDueY1j\XJiaX6gV{BidmRiR{KtUUBxcGG|ZYRCpC=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
MDA-MB-231  NWrBOnlbTnWwY4Tpc44hSXO|YYm= NE[0fGkyODBizszN NHHCeWc1QCCq NVrjW4FPcW6lcnXhd4V{KHSqZTDj[YxtKG63bXLldkBqdiCJMdMgdIhie2ViYX7kJIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hWyCjbnSgS|IuVSCyaHHz[ZPDqA>? M17ZR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
MDA-MB-231 NVjCd21XTnWwY4Tpc44hSXO|YYm= M1PITlAuOTByIN88US=> NIOyUVgzPCCq M2T1[5NmdGWldHn2[Yx6KGmwaHnibZR{KFKjY{GgZYN1cX[jdHnvckB4cXSqb4X0JIlvfGW{ZnXybY5oKHerdHigeIhmKGGldHn2bZR6KG:oIITo[UBkdG:|ZXz5JJJmdGG2ZXSgd41idGxiR2TQZZNmKEOmY{Sy NFfOTYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
MDA-MB-231 M{LSeWN6fG:2b4jpZ4l1gSCDc4PhfS=> NIfYcYExNTFyMDFOwG0> M4DETVQ5KGh? NHGySG1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MDA-MB-468 MXrDfZRwfG:6aXPpeJkhSXO|YYm= M4nGO|AuOTByIN88US=> MlHJOFghcA>? NYHuUVdH\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
T47D M2n4TGN6fG:2b4jpZ4l1gSCDc4PhfS=> NX33ZnBOOC1zMECg{txO MmTZOFghcA>? NFHyfnFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MCF7 NIXwcFFEgXSxdH;4bYNqfHliQYPzZZk> NH;UO|AxNTFyMDFOwG0> NVXIbIh4PDhiaB?= MlW0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MljjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
SKBR3-pMKO.1 M1rD[WZ2dmO2aX;uJGF{e2G7 NFPEXVA2OCEQvF2= NGDUd3ozPCCq MYPpcohq[mm2czDSZYMyKGGldHn2ZZRqd25? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2M{iyOUc,OjF7NEO4NlU9N2F-
SKBR3 NH22SZZHfW6ldHnvckBCe3OjeR?= MonNOVAh|ryP MX[yOEBp NVLKNG4ycW6qaXLpeJMhWmGlMTDhZ5RqfmG2aX;u NWCxeXpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFM5OjVpPkKxPVQ{QDJ3PD;hQi=>
NCI-H1703 MlHRSpVv[3Srb36gRZN{[Xl? MUCwMVUxOCEQvF2= NEHNSHEzPCCq M{jVdYRqdWmwaYPo[ZMh[mG|YXygUmYu|rqEIHHjeIl3cXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= M4ThelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUS5NVYxLz5{MkW0PVE3ODxxYU6=
NCI-H1703 Ml\GSpVv[3Srb36gRZN{[Xl? NFrOcHMyODBizsznM41t NFzHWXczPCCq M{juSJNtd3e|IIDyc4dz\XO|aX;uJJRpem:3Z3igeIhmKEdzwrDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? M3\HWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUS5NVYxLz5{MkW0PVE3ODxxYU6=
NCI-H1703 NFHHbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTaVlFNOC13MECg{txO M4DyUlI1KGh? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHvTNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0PVE3OCd-MkK1OFkyPjB:L3G+
T98MG MX3GeY5kfGmxbjDBd5NigQ>? M1P4NVUxKG2P NX:1cIdNOjRiaB?= NFfTeItFVVOR NX2zVHox\W6qYX7j[ZMhfGinIHHueIlucWe{YYTvdpkh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NYjhV|lbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N|IyOjBpPkKzPFMzOTJyPD;hQi=>
A172MG NHO0SFFHfW6ldHnvckBCe3OjeR?= NF3kcWU2OCCvTR?= NHrTSoUzPCCq M2jafWROW09? M3\NbIVvcGGwY3XzJJRp\SCjboTpcYloemG2b4L5JIVn\mWldDDv[kBmemyxdHnubYI> M4n1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEOyNVIxLz5{M{izNlEzODxxYU6=
U87MG NYHzOWlxTnWwY4Tpc44hSXO|YYm= NHLa[JY2OCCvTR?= MknCNlQhcA>? M1:5e2ROW09? NXXMS5lk\W6qYX7j[ZMhfGinIHHueIlucWe{YYTvdpkh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MmTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
PC40 NFPVeYNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWTHO3FpPTBibV2= NIm0eWIyPDRiaB?= MlXKSG1UVw>? MYflfIhq[mm2czDzfY5memerc4TpZ{BidnSrcILvcIln\XKjdHn2[UBm\m[nY4TzJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHXycI91cW6rYtMg MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh|MkGyNEc,OjN6M{KxNlA9N2F-
PC38 NEXvW4dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWjrdZpKPTBibV2= MlK3NVQ1KGh? M{H4fWROW09? NVHjfIls\XiqaXLpeJMhe3mwZYLnbZN1cWNiYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1eyClb33ibY5m\CC2cnXheI1mdnRid3n0bEBmemyxdHnubYLDqA>? MlHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
T98MG MknFR4VtdCCYaXHibYxqfHliQYPzZZk> MlrLOVAhdU1? MUGxOFQhcA>? MmHPSG1UVw>? M{TLOYV5cGmkaYTzJJN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeJMh[2:vYnnu[YQhfHKnYYTt[Y51KHerdHig[ZJtd3SrbnnixsA> M1HheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEOyNVIxLz5{M{izNlEzODxxYU6=
A172MG NWfySmRzS2WubDDWbYFjcWyrdImgRZN{[Xl? NYDKWo96PTBibV2= NVjmTFVCOTR2IHi= M3G0VGROW09? MkTw[ZhpcWKrdIOgd5lv\XKpaYP0bYMh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0d{Bkd22kaX7l[EB1emWjdH3lcpQhf2m2aDDldoxwfGmwaXNCpC=> NV3HOYE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N|IyOjBpPkKzPFMzOTJyPD;hQi=>
U87MG MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoPSOVAhdU1? M3fBN|E1PCCq NUDrXpd7TE2VTx?= M3KwW4V5cGmkaYTzJJN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeJMh[2:vYnnu[YQhfHKnYYTt[Y51KHerdHig[ZJtd3SrbnnixsA> Mn2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
Ki-67+ CLL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUewUIJ6PTBiwsXN M1;rTVUh\A>? NF71ZXBl\WO{ZXHz[ZMhfGinIH71cYJmeiCxZjDLbU03PywEoFPMUEBk\Wyucx?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyMUKxO{c,OjR3MEGyNVc9N2F-
NIH3T3  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKxRVRLOTByIN88US=> MYKyOOKhcA>? M3XZd4hieyCwbzDzbYdvcW[rY3HueEBqdXCjY4Sgc44h[2WubDD2bYFjcWyrdIm= NUDrbY5MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwN|cxPjBpPkK1NFM4ODZyPD;hQi=>
U2-OS M3PT[2Z2dmO2aX;uJGF{e2G7 MoHHNVAxKM7:TR?= NVXTZYNtOjRiaB?= M3P5WmROW09? MmL2bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{GgdIhie2YEoB?= M4TOTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|I4Lz5{NUGwPVMzPzxxYU6=
SW480  M2PnWGZ2dmO2aX;uJGF{e2G7 NU[zUpMxOTByIN88US=> MnL3NlQhcA>? MULEUXNQ Mm\ybY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{GgdIhie2YEoB?= NFnKRlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVMzPyd-MkWxNFk{Ojd:L3G+
A431 NUDDbXd7TnWwY4Tpc44hSXO|YYm= MmrrNVAxKM7:TR?= MYqyOEBp MXTEUXNQ M4[5eYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFexJJBp[XOnwrC= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUOyO{c,OjVzMEmzNlc9N2F-
U2-OS NFy4bWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;6NVAxKM7:TR?= MWGyOE81QC95MjDo Mle3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NEnLXYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVMzPyd-MkWxNFk{Ojd:L3G+
SW480  MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvvNVAxKM7:TR?= MnHDNlQwPDhxN{KgbC=> NHPZSFBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUOyO{c,OjVzMEmzNlc9N2F-
A431 NWqzWnJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xNFAh|ryP NXTWTm5bOjRxNEivO|IhcA>? NX;4ZmFIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? NUCyS2k1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{OjdpPkK1NVA6OzJ5PD;hQi=>
RBMECs M4HYNWZ2dmO2aX;uJGF{e2G7 NHXHS4YyODBizszNxsA> NUjTZ2QyOzEEoH3pci=> MnnTZoxw[2unczC2Ro57NWODTWCtcYVlcWG2ZXSgZYN1cX[jdHnvckBw\iCUYXOxJIlvKEWPQWCtTWkufHKnYYTl[EBTSk2HQ4O= NHSzRlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1PFA{QSd-Mk[zOVgxOzl:L3G+
human aortic smooth muscle cells NIHUS2dHfW6ldHnvckBCe3OjeR?= MWG1NEB2VQ>? NX7Wcmg2UW6qaXLpeIlwdiCxZjDSZYMyKGKrbnTpcochfG9iUHHrNUBqdiCqdX3hckBid3K2aXOgd41wd3SqIH31d4Nt\SClZXzsd{BifCB3MDD1UUBjgSCVRGOtVGFITSCkYYPl[EBkcGWvaXz1cYlv\XOlZX7j[S=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{N{CzNkc,OTl3MkewN|I9N2F-
human aortic smooth muscle cells NUDkRoVMTnWwY4Tpc44hSXO|YYm= NUPxTpVuOTByIN88US=> MXHJcohq[mm2aX;uJI9nKFKjY{GgZolv\GmwZzD0c{BR[WtzIHnuJIh2dWGwIHHvdpRq[yC|bX;veIghdXW|Y3zlJINmdGy|IHH0JFExOCC3TTDifUBUTFNvUFHHSUBj[XOnZDDjbIVucWy3bXnu[ZNk\W6lZR?= M4j5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUK3NFMzLz5zOUWyO|A{OjxxYU6=
Assay
Methods Test Index PMID
Western blot pCREB / CREB ; OCT4 / SOX2 / Nanog ; active Rac1 / Rac1 25319697 31338333
Immunofluorescence IP3K-A / F-actin ; BART / Rac1 19890013 22745590
In vivo NSC23766 induces mobilization of hematopoietic stem cells/progenitors. Intraperitoneal administration of NSC23766 (2.5 mg/kg) into the ‘‘poorly mobilizing ’’ C57Bl/6 mouse strain leads to a two-fold increase in circulating hematopoietic stem cells/progenitors 6 hr after injection. [2] NSC23766 alleviates lipopolysaccharide-induced acute pulmonary injury in mice. Treatment with NSC23766 at 1 or 3mg/kg not only reduces the inflammatory cells infiltration and MPO activities, but also inhibits pro-inflammatory mediators, tumor necrosis factor-α and interleukin-1β, mRNA expression. NSC23766 also reduces Evans Blue and albumin accumulation in LPS-challenged lungs. [6]

Protocol (from reference)

Kinase Assay:[1]
  • Rho GTPase activity assay:

    Cells are grown in log phase in a 10-cm dish, and are starved in 0.5% serum medium or indicated otherwise for 24 h before lysis in a buffer containing 20 mM Tris HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2, 1% Nonidet P-40, 10% glycerol, and 1× protease inhibitor mixture. Lysates are clarified, the protein concentrations are normalized, and the GTP-bound Rac1 in the lysates is measured by an effector domain pull-down assay. For the His6-PAK1 PBD pull-down assay, cell lysates are incubated with Ni2+-agarose-immobilized His6-PAK1 PBD domain (∼1 μg each) purified from E. coli for 30 min. The Ni2+-agarose co-precipitates are washed twice in the wash buffer and analyzed by immunoblotting with anti-Rac1 monoclonal antibody.

Cell Research:[5]
  • Cell lines: Human breast cancer cells MDA-MB-468
  • Concentrations: 0-100 μM
  • Incubation Time: 2 days
  • Method: Cells (1.5 × 104/mL) are seeded in each well of 96-well tissue culture plates with 200 μL of medium. After 24 hours of plating, the medium is replaced with 200 μL of fresh medium containing NSC23766 at the indicated concentrations. At the end of the treatment period 20 μL of MTS solution are added to each well and incubated at 37 ℃ for 2 hours. Absorbance at 490 nm is read on a 96-well plate reader.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 530.96
Formula

C24H35N7.3HCl

CAS No. 1177865-17-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCN(CC)CCCC(C)NC1=NC(=CC(=N1)NC2=CC3=C(C=C(N=C3C=C2)C)N)C.Cl.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy NSC23766|NSC23766 ic50|NSC23766 price|NSC23766 cost|NSC23766 solubility dmso|NSC23766 purchase|NSC23766 manufacturer|NSC23766 research buy|NSC23766 order|NSC23766 mouse|NSC23766 chemical structure|NSC23766 mw|NSC23766 molecular weight|NSC23766 datasheet|NSC23766 supplier|NSC23766 in vitro|NSC23766 cell line|NSC23766 concentration|NSC23766 nmr|NSC23766 in vivo|NSC23766 clinical trial|NSC23766 inhibitor|NSC23766 Cell Cycle inhibitor